This information was published on 2026-07-28T09:46:06 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2675466 (IR 1927257) |
| (220) |
07 May 2026
|
| (300) |
US, 20 Nov 2025, 99507779
|
| (511) (510) |
Class 5
Therapeutic pharmaceuticals for the treatment of autoimmune diseases; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; pharmaceutical preparations and substances for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders. |
| (540) | MIVSET |
| (550) | Word |
| (730) |
Kyverna Therapeutics, Inc.
|
Find out more about publications on the About page.